Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 245 entries
Sorted by: Best Match Show Resources per page
Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.

Clinical endocrinology

Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Kaur P, Visla J, Karakas S, Berglund L.
PMID: 26341109
Clin Endocrinol (Oxf). 2016 Feb;84(2):229-235. doi: 10.1111/cen.12937. Epub 2015 Oct 05.

OBJECTIVE: Levels of lipoprotein(a), Lp(a), an independent risk factor for cardiovascular disease (CVD), are affected by sex hormones. Women with polycystic ovary syndrome (PCOS) have elevated androgen levels and are at increased CVD risk. We investigated the impact of...

Cite
Enkhmaa B, Anuurad E, Zhang W, et al. Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2015;84(2):229-235doi: 10.1111/cen.12937.
Enkhmaa, B., Anuurad, E., Zhang, W., Abbuthalha, A., Kaur, P., Visla, J., Karakas, S., & Berglund, L. (2016). Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome. Clinical endocrinology, 84(2), 229-235. https://doi.org/10.1111/cen.12937
Enkhmaa, Byambaa, et al. "Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome." Clinical endocrinology vol. 84,2 (2016): 229-235. doi: https://doi.org/10.1111/cen.12937
Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Kaur P, Visla J, Karakas S, Berglund L. Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016 Feb;84(2):229-235. doi: 10.1111/cen.12937. Epub 2015 Oct 05. PMID: 26341109; PMCID: PMC4779071.
Copy Download .nbib Format: NLM
Abstracts of the Endocrine Society of Australia Annual Scientific Meeting 2016.

Clinical endocrinology

[No authors listed]
PMID: 28111774
Clin Endocrinol (Oxf). 2017 Jan;86:1-68. doi: 10.1111/cen.13259.

No abstract available.

Cite
Abstracts of the Endocrine Society of Australia Annual Scientific Meeting 2016. Clin Endocrinol (Oxf). 2017;86:1-68doi: 10.1111/cen.13259.
(2017). Abstracts of the Endocrine Society of Australia Annual Scientific Meeting 2016. Clinical endocrinology, 861-68. https://doi.org/10.1111/cen.13259
"Abstracts of the Endocrine Society of Australia Annual Scientific Meeting 2016." Clinical endocrinology vol. 86 (2017): 1-68. doi: https://doi.org/10.1111/cen.13259
Abstracts of the Endocrine Society of Australia Annual Scientific Meeting 2016. Clin Endocrinol (Oxf). 2017 Jan;86:1-68. doi: 10.1111/cen.13259. PMID: 28111774.
Copy Download .nbib Format: NLM
Quantification and regulation of adipsin in human cerebrospinal fluid (CSF).

Clinical endocrinology

Schmid A, Hochberg A, Berghoff M, Schlegel J, Karrasch T, Kaps M, Schäffler A.
PMID: 26186410
Clin Endocrinol (Oxf). 2016 Feb;84(2):194-202. doi: 10.1111/cen.12856. Epub 2015 Aug 26.

CONTEXT: Data on quantification and regulation of adipsin in human cerebrospinal fluid (CSF) are sparse, and the physiological role of adipsin as an adipokine crossing the blood-brain barrier (BBB) is uncertain.OBJECTIVES: This study quantified adipsin concentrations in paired serum...

Cite
Schmid A, Hochberg A, Berghoff M, et al. Quantification and regulation of adipsin in human cerebrospinal fluid (CSF). Clin Endocrinol (Oxf). 2015;84(2):194-202doi: 10.1111/cen.12856.
Schmid, A., Hochberg, A., Berghoff, M., Schlegel, J., Karrasch, T., Kaps, M., & Schäffler, A. (2016). Quantification and regulation of adipsin in human cerebrospinal fluid (CSF). Clinical endocrinology, 84(2), 194-202. https://doi.org/10.1111/cen.12856
Schmid, Andreas, et al. "Quantification and regulation of adipsin in human cerebrospinal fluid (CSF)." Clinical endocrinology vol. 84,2 (2016): 194-202. doi: https://doi.org/10.1111/cen.12856
Schmid A, Hochberg A, Berghoff M, Schlegel J, Karrasch T, Kaps M, Schäffler A. Quantification and regulation of adipsin in human cerebrospinal fluid (CSF). Clin Endocrinol (Oxf). 2016 Feb;84(2):194-202. doi: 10.1111/cen.12856. Epub 2015 Aug 26. PMID: 26186410.
Copy Download .nbib Format: NLM
Is there a role for an ultrasensitive thyroglobulin assay in patients with serum antithyroglobulin antibodies? A large (Australian) cohort study in differentiated thyroid cancer.

Clinical endocrinology

McGrath RT, Preda VA, Clifton-Bligh P, Robinson B, Sywak M, Delbridge L, Ward P, Clifton-Bligh RJ, Learoyd DL.
PMID: 25656320
Clin Endocrinol (Oxf). 2016 Feb;84(2):271-277. doi: 10.1111/cen.12736. Epub 2015 Feb 27.

OBJECTIVE: Serum thyroglobulin (Tg) is a marker of residual differentiated thyroid cancer (DTC) after total thyroidectomy; however, circulating antithyroglobulin antibodies (TgAb) may interfere with the immunoassay for Tg. Ultrasensitive assays may have a more significant role in detecting circulating...

Cite
McGrath RT, Preda VA, Clifton-Bligh P, et al. Is there a role for an ultrasensitive thyroglobulin assay in patients with serum antithyroglobulin antibodies? A large (Australian) cohort study in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2015;84(2):271-277doi: 10.1111/cen.12736.
McGrath, R. T., Preda, V. A., Clifton-Bligh, P., Robinson, B., Sywak, M., Delbridge, L., Ward, P., Clifton-Bligh, R. J., & Learoyd, D. L. (2016). Is there a role for an ultrasensitive thyroglobulin assay in patients with serum antithyroglobulin antibodies? A large (Australian) cohort study in differentiated thyroid cancer. Clinical endocrinology, 84(2), 271-277. https://doi.org/10.1111/cen.12736
McGrath, Rachel T, et al. "Is there a role for an ultrasensitive thyroglobulin assay in patients with serum antithyroglobulin antibodies? A large (Australian) cohort study in differentiated thyroid cancer." Clinical endocrinology vol. 84,2 (2016): 271-277. doi: https://doi.org/10.1111/cen.12736
McGrath RT, Preda VA, Clifton-Bligh P, Robinson B, Sywak M, Delbridge L, Ward P, Clifton-Bligh RJ, Learoyd DL. Is there a role for an ultrasensitive thyroglobulin assay in patients with serum antithyroglobulin antibodies? A large (Australian) cohort study in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2016 Feb;84(2):271-277. doi: 10.1111/cen.12736. Epub 2015 Feb 27. PMID: 25656320.
Copy Download .nbib Format: NLM
Metformin and polycystic ovary syndrome.

Clinical endocrinology

Kelestimur F, Unluhizarci K, Bayram F, Sahin Y, Tutus A.
PMID: 10671956
Clin Endocrinol (Oxf). 2000 Feb;52(2):244-6. doi: 10.1046/j.1365-2265.2000.0945a.x.

No abstract available.

Cite
Kelestimur F, Unluhizarci K, Bayram F, et al. Metformin and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2000;52(2):244-6doi: 10.1046/j.1365-2265.2000.0945a.x.
Kelestimur, F., Unluhizarci, K., Bayram, F., Sahin, Y., & Tutus, A. (2000). Metformin and polycystic ovary syndrome. Clinical endocrinology, 52(2), 244-6. https://doi.org/10.1046/j.1365-2265.2000.0945a.x
Kelestimur, et al. "Metformin and polycystic ovary syndrome." Clinical endocrinology vol. 52,2 (2000): 244-6. doi: https://doi.org/10.1046/j.1365-2265.2000.0945a.x
Kelestimur F, Unluhizarci K, Bayram F, Sahin Y, Tutus A. Metformin and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2000 Feb;52(2):244-6. doi: 10.1046/j.1365-2265.2000.0945a.x. PMID: 10671956.
Copy Download .nbib Format: NLM
Clinical associations of maternal thyroid function with foetal brain development: Epidemiological interpretation and overview of available evidence.

Clinical endocrinology

Korevaar TIM, Tiemeier H, Peeters RP.
PMID: 29693263
Clin Endocrinol (Oxf). 2018 Aug;89(2):129-138. doi: 10.1111/cen.13724. Epub 2018 May 16.

Thyroid hormone is an important regulator of early brain development, particularly during early stages of gestation during which foetal thyroid hormone availability depends on the maternal transfer of thyroid hormones. There is a wide range of experimental studies showing...

Cite
Korevaar TIM, Tiemeier H, Peeters RP. Clinical associations of maternal thyroid function with foetal brain development: Epidemiological interpretation and overview of available evidence. Clin Endocrinol (Oxf). 2018;89(2):129-138doi: 10.1111/cen.13724.
Korevaar, T. I. M., Tiemeier, H., & Peeters, R. P. (2018). Clinical associations of maternal thyroid function with foetal brain development: Epidemiological interpretation and overview of available evidence. Clinical endocrinology, 89(2), 129-138. https://doi.org/10.1111/cen.13724
Korevaar, Tim I M, et al. "Clinical associations of maternal thyroid function with foetal brain development: Epidemiological interpretation and overview of available evidence." Clinical endocrinology vol. 89,2 (2018): 129-138. doi: https://doi.org/10.1111/cen.13724
Korevaar TIM, Tiemeier H, Peeters RP. Clinical associations of maternal thyroid function with foetal brain development: Epidemiological interpretation and overview of available evidence. Clin Endocrinol (Oxf). 2018 Aug;89(2):129-138. doi: 10.1111/cen.13724. Epub 2018 May 16. PMID: 29693263.
Copy Download .nbib Format: NLM
Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas.

Clinical endocrinology

Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, Sywak M, Sidhu S, Delbridge LW, Robinson BG, Schembri G, Clifton-Bligh RJ.
PMID: 29741215
Clin Endocrinol (Oxf). 2018 Aug;89(2):139-147. doi: 10.1111/cen.13737. Epub 2018 May 24.

CONTEXT: Diagnosis of paragangliomas (PGL) and phaeochromocytomas (PC) can be challenging particularly if the tumour is small. Detection of metastatic disease is important for comprehensive management of malignant PC/PGL. Somatostatin receptor imaging (SRI) agents have high sensitivity for these...

Cite
Gild ML, Naik N, Hoang J, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018;89(2):139-147doi: 10.1111/cen.13737.
Gild, M. L., Naik, N., Hoang, J., Hsiao, E., McGrath, R. T., Sywak, M., Sidhu, S., Delbridge, L. W., Robinson, B. G., Schembri, G., & Clifton-Bligh, R. J. (2018). Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clinical endocrinology, 89(2), 139-147. https://doi.org/10.1111/cen.13737
Gild, Matti L, et al. "Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas." Clinical endocrinology vol. 89,2 (2018): 139-147. doi: https://doi.org/10.1111/cen.13737
Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, Sywak M, Sidhu S, Delbridge LW, Robinson BG, Schembri G, Clifton-Bligh RJ. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018 Aug;89(2):139-147. doi: 10.1111/cen.13737. Epub 2018 May 24. PMID: 29741215.
Copy Download .nbib Format: NLM
Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules.

Clinical endocrinology

Giovanella L, Piccardo A, Pezzoli C, Bini F, Ricci R, Ruberto T, Trimboli P.
PMID: 29741290
Clin Endocrinol (Oxf). 2018 Aug;89(2):219-225. doi: 10.1111/cen.13738. Epub 2018 May 24.

PURPOSE: We compared the effectiveness of high intensity focused ultrasound (HIFU) and radioiodine (RAI) to treat patients carrying toxic thyroid nodule (TTN). Normalization of serum thyrotropin (TSH) 1 year after treatment was the primary end-point; concurrent changes in nodules'...

Cite
Giovanella L, Piccardo A, Pezzoli C, et al. Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules. Clin Endocrinol (Oxf). 2018;89(2):219-225doi: 10.1111/cen.13738.
Giovanella, L., Piccardo, A., Pezzoli, C., Bini, F., Ricci, R., Ruberto, T., & Trimboli, P. (2018). Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules. Clinical endocrinology, 89(2), 219-225. https://doi.org/10.1111/cen.13738
Giovanella, Luca, et al. "Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules." Clinical endocrinology vol. 89,2 (2018): 219-225. doi: https://doi.org/10.1111/cen.13738
Giovanella L, Piccardo A, Pezzoli C, Bini F, Ricci R, Ruberto T, Trimboli P. Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules. Clin Endocrinol (Oxf). 2018 Aug;89(2):219-225. doi: 10.1111/cen.13738. Epub 2018 May 24. PMID: 29741290.
Copy Download .nbib Format: NLM
The Authors' Reply: In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient.

Clinical endocrinology

Turan I, Topaloglu AK, Yuksel B.
PMID: 29772605
Clin Endocrinol (Oxf). 2018 Aug;89(2):241-242. doi: 10.1111/cen.13742. Epub 2018 Jun 03.

No abstract available.

Cite
Turan I, Topaloglu AK, Yuksel B. The Authors' Reply: In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient. Clin Endocrinol (Oxf). 2018;89(2):241-242doi: 10.1111/cen.13742.
Turan, I., Topaloglu, A. K., & Yuksel, B. (2018). The Authors' Reply: In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient. Clinical endocrinology, 89(2), 241-242. https://doi.org/10.1111/cen.13742
Turan, Ihsan, et al. "The Authors' Reply: In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient." Clinical endocrinology vol. 89,2 (2018): 241-242. doi: https://doi.org/10.1111/cen.13742
Turan I, Topaloglu AK, Yuksel B. The Authors' Reply: In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient. Clin Endocrinol (Oxf). 2018 Aug;89(2):241-242. doi: 10.1111/cen.13742. Epub 2018 Jun 03. PMID: 29772605.
Copy Download .nbib Format: NLM
In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient.

Clinical endocrinology

Hanukoglu A, Hanukoglu I.
PMID: 29702750
Clin Endocrinol (Oxf). 2018 Aug;89(2):240-241. doi: 10.1111/cen.13730. Epub 2018 May 15.

No abstract available.

Cite
Hanukoglu A, Hanukoglu I. In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient. Clin Endocrinol (Oxf). 2018;89(2):240-241doi: 10.1111/cen.13730.
Hanukoglu, A., & Hanukoglu, I. (2018). In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient. Clinical endocrinology, 89(2), 240-241. https://doi.org/10.1111/cen.13730
Hanukoglu, Aaron, and Hanukoglu, Israel. "In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient." Clinical endocrinology vol. 89,2 (2018): 240-241. doi: https://doi.org/10.1111/cen.13730
Hanukoglu A, Hanukoglu I. In systemic pseudohypoaldosteronism type 1 skin manifestations are not rare and the disease is not transient. Clin Endocrinol (Oxf). 2018 Aug;89(2):240-241. doi: 10.1111/cen.13730. Epub 2018 May 15. PMID: 29702750.
Copy Download .nbib Format: NLM
Sex-specific associations of insulin-like peptides in cord blood with size at birth.

Clinical endocrinology

van Poppel MN, Eder M, Lang U, Desoye G.
PMID: 29751363
Clin Endocrinol (Oxf). 2018 Aug;89(2):187-193. doi: 10.1111/cen.13739. Epub 2018 May 29.

OBJECTIVE: Insulin-like peptides (insulin, IGF-1, IGF-2) are essential regulators of foetal growth. We assessed the role of these peptides for birth size in a sex-specific manner.DESIGN: Cross-sectional cohort analysis.PATIENTS AND MEASUREMENTS: In 369 neonates, cord blood insulin, C-peptide, IGF-1...

Cite
van Poppel MN, Eder M, Lang U, et al. Sex-specific associations of insulin-like peptides in cord blood with size at birth. Clin Endocrinol (Oxf). 2018;89(2):187-193doi: 10.1111/cen.13739.
van Poppel, M. N., Eder, M., Lang, U., & Desoye, G. (2018). Sex-specific associations of insulin-like peptides in cord blood with size at birth. Clinical endocrinology, 89(2), 187-193. https://doi.org/10.1111/cen.13739
van Poppel, Mireille Nm, et al. "Sex-specific associations of insulin-like peptides in cord blood with size at birth." Clinical endocrinology vol. 89,2 (2018): 187-193. doi: https://doi.org/10.1111/cen.13739
van Poppel MN, Eder M, Lang U, Desoye G. Sex-specific associations of insulin-like peptides in cord blood with size at birth. Clin Endocrinol (Oxf). 2018 Aug;89(2):187-193. doi: 10.1111/cen.13739. Epub 2018 May 29. PMID: 29751363.
Copy Download .nbib Format: NLM
Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy.

Clinical endocrinology

Liu L, Xie W, Song Z, Wang T, Li X, Gao Y, Li Y, Zhang J, Guo X.
PMID: 34486152
Clin Endocrinol (Oxf). 2022 Feb;96(2):132-138. doi: 10.1111/cen.14585. Epub 2021 Sep 05.

OBJECTIVE: Measurements of plasma free metanephrines (MNs), including MN and normetanephrine, provide high sensitivity and specificity for the diagnosis of pheochromocytoma and paraganglioma (PPGL). 3-Methoxytyramine (3-MT) and chromogranin A (CgA) may allow the detection of dopamine-producing or biochemically silent...

Cite
Liu L, Xie W, Song Z, et al. Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy. Clin Endocrinol (Oxf). 2021;96(2):132-138doi: 10.1111/cen.14585.
Liu, L., Xie, W., Song, Z., Wang, T., Li, X., Gao, Y., Li, Y., Zhang, J., & Guo, X. (2022). Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy. Clinical endocrinology, 96(2), 132-138. https://doi.org/10.1111/cen.14585
Liu, Lu, et al. "Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy." Clinical endocrinology vol. 96,2 (2022): 132-138. doi: https://doi.org/10.1111/cen.14585
Liu L, Xie W, Song Z, Wang T, Li X, Gao Y, Li Y, Zhang J, Guo X. Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy. Clin Endocrinol (Oxf). 2022 Feb;96(2):132-138. doi: 10.1111/cen.14585. Epub 2021 Sep 05. PMID: 34486152.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 245 entries